Infection Prevention in Hematopoietic Stem Cell Transplantation
Introduction to Infection Prevention
- The American Society of Oncology recommends the use of fluoroquinolones for antibacterial prophylaxis, fluconazole or posaconazole for antifungal prophylaxis, and trimethoprim-sulfamethoxazole for prevention of Pneumocystis jiroveci in patients undergoing allogeneic hematopoietic stem cell transplantation 1
Antibacterial Prophylaxis
- Fluoroquinolones (ciprofloxacin or ofloxacin) are recommended with a level of evidence AI to prevent bacterial infections during the period of neutropenia, with a dosage of 500 mg every 12 hours orally, starting from conditioning until neutrophil recovery 1
- Fluoroquinolone prophylaxis has been shown to significantly reduce gram-negative bacterial infections, decrease the duration of febrile episodes, and lower the rate of documented infections 1
- It is not recommended to add routine prophylaxis against gram-positive bacteria (level DIII), reserving it only for high-risk patients or as secondary prophylaxis 1
Antifungal Prophylaxis
- In patients with chronic active graft-versus-host disease (GVHD) or splenectomized patients, prophylaxis against pneumococcus is recommended (level BII) 1
- Trimethoprim-sulfamethoxazole used for PCP prophylaxis also provides protection against pneumococcus 1
Prophylaxis against Pneumocystis jiroveci
- Trimethoprima-sulfametoxazol is recommended as first-line prophylaxis (level AII) with a dosage of 160/800 mg (1 double-strength tablet) three times a week, starting from grafting until at least 6 months post-transplantation 1
- Alternatives (when TMP-SMX is not tolerated) include dapsone and pentamidina aerosolizada, although these agents have been associated with higher infection rates 1
Viral Prophylaxis
- All transplant candidates should be evaluated for IgG antibodies against herpes virus group 1
- Aciclovir or Valaciclovir should be used to prevent reactivation of HSV and VZV, with a duration of at least until day +30 for HSV and up to 1 year for VZV 1
- Pre-transplant CMV IgG antibody testing should be performed, and a preventive strategy based on weekly viral load monitoring should be implemented 1
- In CMV-negative recipients, a CMV-negative donor should be preferred when possible, and CMV-negative or leucoreduced blood products should be used 1
Other Infections
- Pre-transplant serology should be performed, and in seropositive patients with acute GVHD, prophylaxis with TMP-SMZ, clindamycin, or pyrimethamine with leucovorin should be considered 1
- Patients should avoid foods with a risk of contamination (nuts, unpasteurized milk, raw eggs) 1
Vaccination
- A revaccination program should be initiated 1 year after transplantation, and immunity against specific pathogens should be evaluated before starting revaccination 1
Adjustment of Prophylaxis
- Prophylaxis should be adjusted according to local epidemiology and resistance patterns 1